News - Indevus Pharmaceuticals Inc.
WALTHAM, Mass., Aug. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that Glenn L. Cooper, M.D. has been elected to its Board of Directors. Dr.
CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter. Total revenues during the second quarter of 2009 increased 22 percent to $373.1 million compared with $306.2 million in the second quarter of 2008.
CHADDS FORD, Pa., April 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter of 2009, including results beginning on February 23, 2009 for Indevus Pharmaceuticals, which Endo acquired during the quarter. Net sales during the first quarter of 2009 increased 16% to $335.3 million compared with $290.3 million in the first quarter of 2008.
CHADDS FORD, Pa., March 23 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced the successful completion of its acquisition of Indevus Pharmaceuticals, Inc.
